All In Biotech

Drug Trial Radar · NCT04657289

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

A Phase IIIb, Global, Multicenter, Randomized, Visual Assessor-Masked Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 451 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

451

Actual

Start

Jul 14, 2021

Primary completion

Feb 4, 2027

Study completion Feb 4, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • RanibizumabDrug

    Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals

  • Port Delivery System with RanibizumabDevice

    Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Best-corrected visual acuity (BCVA) score averaged over Weeks 68 and 72, as assessed using the ETDRS chart starting at a distance of 4 metersTime frame: Baseline to Week 72

Locations

104 sites in 16 countries. Site status is shown where the registry gives one.

  • Centro Oftalmologico Dr. Charles S.A.

    Capital Federal, Argentina

  • Oftalmos

    Capital Federal, Argentina

  • Grupo Laser Vision

    Rosario, Argentina

  • Eyeclinic Albury Wodonga

    Albury, New South Wales, Australia

  • Eye and Retina Consultants

    Hurstville, New South Wales, Australia

  • Retina Associates Liverpool

    Liverpool, New South Wales, Australia

  • Retina and Macula Specialists

    Miranda, New South Wales, Australia

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia

  • Sydney Retina Clinic and Day Surgery

    Sydney, New South Wales, Australia

  • Queensland Eye Institute

    Woolloongabba, Queensland, Australia

  • Centre For Eye Research Australia

    East Melbourne, Victoria, Australia

  • Retina Specialists Victoria

    Rowville, Victoria, Australia

  • The Lions Eye Institute

    Nedlands, Western Australia, Australia

  • LKH-Univ.Klinikum Graz

    Graz, Austria

  • Medizinische Universitat Wien

    Vienna, Austria

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Botelho Hospital da Visao

    Blumenau, Santa Catarina, Brazil

  • Retina Clinic

    São Paulo, São Paulo, Brazil

  • Universidade Federal de Sao Paulo - UNIFESPX

    São Paulo, São Paulo, Brazil

  • Instituto da Visao IPEPO

    São Paulo, São Paulo, Brazil

  • Hosp de Olhos de Sorocaba

    Sorocaba, São Paulo, Brazil

  • Centre Retine Gallien

    Bordeaux, France

  • Hopital de la croix rousse

    Lyon, France

  • Centre Paradis Monticelli

    Marseille, France

  • Hopital Lariboisiere

    Paris, France

  • Fondation Rothschild

    Paris, France

  • Universitatsklinikum Bonn

    Bonn, Germany

  • Universitatsklinikum Koln

    Cologne, Germany

  • Medizinische Universitat Lausitz ? Carl Thiem

    Cottbus, Germany

  • Universitätsklinikum Freiburg, Klinik für Augenheilkunde

    Freiburg im Breisgau, Germany

  • Universitatsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Klinikum der Stadt Ludwigshafen am Rhein gGmbH

    Ludwigshafen, Germany

  • LMU Klinikum der Universitat, Augenklinik

    München, Germany

  • Augenabteilung am St. Franziskus-Hospital

    Münster, Germany

  • Universitatsklinikum Munster

    Münster, Germany

  • Knappschaftsklinikum Saar GmbH

    Sulzbach, Germany

  • Universitatsklinikum Tubingen

    Tübingen, Germany

  • Universitatsklinikum Ulm, Augenklinik und Poliklinik

    Ulm, Germany

  • Rambam Medical Center

    Haifa, Israel

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.